219 results match your criteria Reactive Perforating Collagenosis


Reactive perforating collagenosis successfully treated with dupilumab.

Australas J Dermatol 2022 May 28. Epub 2022 May 28.

Dermatology Department, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.

View Article and Full-Text PDF

Regression of acquired reactive perforating collagenosis after dipeptidyl peptidase-4 inhibitor cessation.

J Dermatol 2022 Mar 22. Epub 2022 Mar 22.

Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

View Article and Full-Text PDF

Acquired Reactive Perforating Collagenosis Occurring in Association With Nonred Ink Tattoo.

Am J Dermatopathol 2022 Mar 1. Epub 2022 Mar 1.

St. Luke's/Temple University Lewis Katz School of Medicine, Bethlehem, PA; and Department of Dermatology, St. Luke's University Health System, St. Luke's/Temple School of Medicine, Bethlehem, PA.

Abstract: Perforating dermatosis is a group of skin conditions in which there is transdermal elimination of collagen, elastic fibers, or other dermal connective tissue. Perforating dermatosis can be genetic or acquired, known as acquired perforating dermatosis (APD). When collagen is the primary extruded material in acquired cases, the disease is designated as acquired reactive perforating collagenosis (RPC). Read More

View Article and Full-Text PDF

Crusted Umbilicated Papules in a Child.

Dermatol Pract Concept 2022 Feb 1;12(1):e2022002. Epub 2022 Jan 1.

Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

View Article and Full-Text PDF
February 2022

Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD.

Immun Inflamm Dis 2022 03 24;10(3):e574. Epub 2021 Dec 24.

Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China.

The management of acquired reactive perforating collagenosis (ARPC) is challenging. Here, we shared two cases of ARPC combined with elderly atopic dermatitis (AD) that did not respond well to conventional treatment but responded well to the monotherapy of dupilumab, which suggests that dupilumab may be an alternative option for the treatment. Read More

View Article and Full-Text PDF

A giant variant of acquired reactive perforating collagenosis.

Int J Dermatol 2022 07 24;61(7):e250-e252. Epub 2021 Jul 24.

Department of Dermatology, Osaka City General Hospital, Osaka, Japan.

View Article and Full-Text PDF

Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products.

Clin Exp Dermatol 2022 Jan 27;47(1):80-85. Epub 2021 Aug 27.

Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

Background: Acquired perforating dermatoses (APDs) are characterized by transepidermal elimination of skin materials. Altered glycation of dermal components may be involved in pathogenesis.

Aim: To assess whether patients affected by APDs have increased levels of cutaneous advanced glycation end-products (AGEs). Read More

View Article and Full-Text PDF
January 2022

Successful treatment of acquired reactive perforating collagenosis with itraconazole.

Eur J Med Res 2021 Jul 13;26(1):74. Epub 2021 Jul 13.

Dermatopathology, Shanghai Skin Disease Hospital, No. 1278 Baode Road, Zhabei District, Shanghai, 200443, China.

Background: Acquired reactive perforating collagenosis (ARPC) is a rare form of transepithelial elimination in which altered collagen is extruded through the epidermis.

Case Presentation: A 23-year-old male presented with cup-like ulcerated lesions on his limbs since 3 months. A series of serological and immunological tests showed no abnormalities. Read More

View Article and Full-Text PDF

Erlotinib-induced reactive perforating collagenosis in a case of lung adenocarcinoma.

Indian J Dermatol Venereol Leprol 2021 [SEASON];87(4):548-551

Dermatology and Plastic Surgery Center, The Third Affiliated Hospital of Chongqing Medical University (General Hospital), Chongqing, China.

View Article and Full-Text PDF
January 2022

Trauma-induced acquired reactive perforating collagenosis.

An Bras Dermatol 2021 May-Jun;96(3):392-393. Epub 2021 Mar 20.

Patology Service, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.

View Article and Full-Text PDF

Acquired Reactive Perforating Collagenosis: A Case Report.

Cureus 2021 Feb 27;13(2):e13583. Epub 2021 Feb 27.

Dermatology, Cheikh Khalifa International University Hospital, Mohammed VI University of Health Sciences, Casablanca, MAR.

Reactive perforating collagenosis (RPC) is a rare form of dermatosis. It forms with perforating folliculitis, Kyrle's disease, and serpiginous perforating elastosis, which is a group of perforating dermatosis. RPC can be hereditary with autosomal dominant transmission or it can be acquired, which is usually observed in diabetics with chronic renal failure. Read More

View Article and Full-Text PDF
February 2021

Necrotic plaques in an elderly male.

JRSM Open 2021 Feb 11;12(2):2054270420981452. Epub 2021 Feb 11.

Department of Dermatology, Ealing Hospital, Southall, UB1 3HW, UK.

Reactive perforating collagenosis is commonly recognised as an unusual form of transepithelial elimination of collagen and elastin fibres which are extruded through the epidermis in patients with a genetic predisposition or underlying diseases, such as diabetes mellitus or renal diseases. We present the unusual case of an 87-year-old diabetic male with a giant form of reactive perforating collagenosis and review the available literature. Read More

View Article and Full-Text PDF
February 2021

Dermoscopic Patterns of Acquired Reactive Perforating Collagenosis.

Dermatol Pract Concept 2021 Jan 7;11(1):e2020085. Epub 2020 Dec 7.

Department of Dermatology, Faculty of Medicine, Kirşehir Ahi Evran University, Kirşehir, Turkey.

View Article and Full-Text PDF
January 2021

Case of acquired reactive perforating collagenosis induced by panitumumab for colon cancer.

J Dermatol 2021 Feb 2;48(2):e114-e115. Epub 2020 Dec 2.

Department of Dermatological Oncology, National Cancer Center Hospital, Tokyo, Japan.

View Article and Full-Text PDF
February 2021

Reactive perforating collagenosis: a rare side effect associated with sorafenib.

Rev Esp Enferm Dig 2020 Dec;112(12):960-961

Dermatología, Hospital Universitario Príncipe de Asturias.

We present the case of a patient with a debut of reactive perforating collagenosis associated with the use of Sorafenib for stage IV hepatocarcinoma, very successfully controlled with local corticotherapy and systemic antihistamines. This is an extremely rare side effect associated with this treatment, as only another eleven cases of acquired perforating dermatoses associated with Sorafenib or other multi-kinase inhibitors have been found in the medical literature. Given the unusual nature of this presentation, high clinical suspicion and a correct histopathological study are indispensable for its correct filiation and treatment. Read More

View Article and Full-Text PDF
December 2020

Koebnerization of acquired reactive perforating collagenosis after wet cupping successfully treated with UVA1 phototherapy.

Dermatol Ther 2020 11 23;33(6):e14540. Epub 2020 Nov 23.

Department of Dermatology, Istanbul Medeniyet University Medical Faculty, Goztepe Training and Research Hospital, Istanbul, Turkey.

View Article and Full-Text PDF
November 2020

Reactive perforating collagenosis secondary to mesotherapy: first reported case.

J Biol Regul Homeost Agents 2020 Sep-Oct;34(5):1963-1965

Physical and Rehabilitation Medicine, Department of Clinical Sciences and Translational Medicine, Tor Vergata University, Rome, Italy.

View Article and Full-Text PDF
January 2021

Evaluation of clinicopathological and treatment characteristics of 80 patients with acquired perforating dermatosis.

Dermatol Ther 2020 11 5;33(6):e14465. Epub 2020 Nov 5.

Department of Pathology, University of Health Science (HSU) Istanbul Training and Research Hospital, Istanbul, Turkey.

Acquired perforating dermatosis (APD) is a group of a rare dermatological disorder characterized by elimination of dermal connective tissue through epidermis. We aimed to evaluate the characteristics of patients diagnosed with APD and to determine the differences in comorbidities according to subtypes of APD. A retrospective, observational, cross-sectional study was designed. Read More

View Article and Full-Text PDF
November 2020

Clinical practice guide for the treatment of perforating dermatosis.

J Dermatol 2020 Dec 23;47(12):1374-1382. Epub 2020 Oct 23.

Department of Dermatology, Juntendo University Urayasu Hospital, Urayasu, Japan.

Perforating dermatoses are a heterogeneous skin disease group defined by transepidermal elimination of various skin materials. Four classical forms of primary perforating dermatosis have been described, where the transepidermal elimination mechanism represents the hallmark of the disease: acquired reactive perforating collagenosis, elastosis perforans serpiginosa, Kyrle's disease and perforating folliculitis. Acquired reactive perforating collagenosis presents with transepidermal elimination of collagen fibers. Read More

View Article and Full-Text PDF
December 2020

Doxycycline Combined with NB-UVB Phototherapy for Acquired Reactive Perforating Collagenosis.

Ther Clin Risk Manag 2020 24;16:917-921. Epub 2020 Sep 24.

Department of Dermatology, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, People's Republic of China.

Background: Acquired reactive perforating collagenosis is a rare skin disease characterized by the discharge of collagen fibers through the epidermis. There is no standard treatment for this disease currently. Here, we report a case of ARPC that has been successfully treated and cured. Read More

View Article and Full-Text PDF
September 2020

Case for diagnosis. Hyperpigmented and excoriated papules and nodules in a diabetic patient.

An Bras Dermatol 2020 Nov - Dec;95(6):757-759. Epub 2020 Sep 13.

Department of Pathology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

Reactive perforating collagenosis is a rare perforating dermatosis clinically characterized by intensely pruritic hyperpigmented papules, plaques, and nodules with a central keratotic plug. Histopathology reveals transepidermal elimination of collagen fibers. Its pathophysiology is still under investigation, but the acquired form has been linked to systemic conditions such as diabetes mellitus and chronic kidney disease. Read More

View Article and Full-Text PDF
November 2020

Acquired Reactive Perforating Collagenosis Associated with Linear Immunoglobulin A Bullous Disease.

Acta Derm Venereol 2020 Sep 23;100(16):adv00268. Epub 2020 Sep 23.

Department of Dermatology, Children's Hospital of Chongqing Medical University, 400014 ChongQing, China. E-mail:

View Article and Full-Text PDF
September 2020

Acquired reactive perforating collagenosis in association with pregnancy.

Eur J Obstet Gynecol Reprod Biol 2020 Oct 1;253:339-341. Epub 2020 Aug 1.

Department of Dermatology, St Helens and Knowsley Teaching Hospitals NHS Trust, Marshalls Cross Road, St Helens, WA9 3DA, United Kingdom. Electronic address:

View Article and Full-Text PDF
October 2020

Reactive Perforating Collagenosis; An Uncontrolled Pruritus That Left You Scratching Your Head.

Cureus 2020 Jul 14;12(7):e9175. Epub 2020 Jul 14.

Internal Medicine, State University of New York Upstate Medical University, Syracuse, USA.

Acquired perforating collagenosis is a rare disease of altered collagen formation that is extruded through the epidermis. It is most commonly seen in patients with microvascular disease including longstanding diabetes and chronic kidney disease (CKD). Due to the rarity of the disease, no large randomized clinical studies have been performed to determine the most efficacious method of treatment. Read More

View Article and Full-Text PDF

Acquired reactive perforating collagenosis with chondrodermatitis nodularis chronica helicis.

J Dermatol 2020 Oct 30;47(10):e362-e364. Epub 2020 Jul 30.

Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

View Article and Full-Text PDF
October 2020

Acquired Reactive Perforating Collagenosis.

Clin Exp Nephrol 2020 Nov 14;24(11):1086-1087. Epub 2020 Jul 14.

Divison of Nephrology, University of Utah, Salt Lake City, UT, 84132, USA.

View Article and Full-Text PDF
November 2020

Acquired reactive perforating collagenosis.

Chin Med J (Engl) 2020 Sep;133(17):2119-2120

Department of Dermatology, Peking University People's Hospital, Beijing 100044, China.

View Article and Full-Text PDF
September 2020

Berardinelli-Seip Syndrome and Essential Thrombocytosis: An Unusual Association.

Oman Med J 2020 May 30;35(3):e135. Epub 2020 Jun 30.

Department of Internal Medicine, Endocrine Division, King Hussein Medical Centre, Amman, Jordan.

Congenital generalized lipodystrophy (Berardinelli-Seip syndrome) is an autosomal recessive condition, presenting during infancy with generalized loss of fat. We report a 30-year-old female patient with diabetes who has acromegaloid features, prominent umbilicus, prominent muscles, prominent subcutaneous veins, and gross hepatomegaly. Near-total loss of subcutaneous fat was confirmed by whole-body magnetic resonance imaging and laboratory data revealed significant hypertriglyceridemia, uncontrolled diabetes mellitus, and heavy proteinuria with stage IIIa chronic kidney disease. Read More

View Article and Full-Text PDF

Reflectance confocal microscopic appearance of acquired reactive perforating collagenosis.

Skin Res Technol 2021 01 28;27(1):111-112. Epub 2020 Jun 28.

Department of Pathology, Hospital for Skin Disease and Institute of Dermatology, Peking Union Medical College & Chinese Academy of Medical Sciences, Nanjing, China.

View Article and Full-Text PDF
January 2021